— New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 —  — Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 — — Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer — — Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson’s Disease Strategy — CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today...

MONTREAL, Nov. 07, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the third quarter of 2025. Highlights Financial resultsEBITDA(A)1, operating income and net earnings decline in Q3-2025:Production up 7% (9% on a Combined1 basis)2 from Q3-2024, owing mainly to the impact of newly commissioned sites in Europe, yet 13% (13%) below anticipated production1 because of unfavourable weather conditions in North America and to a lesser extent in Europe; Operating loss of $1 million (income of $13 million) in Q3-2025, down $8 million ($9 million) from Q3-2024; EBITDA(A) of $85 million ($108 million) in Q3-2025, down $2 million ($1 million) from Q3-2024 as a consequence of lower prices under short-term power purchase agreements in France, only partially offset by the...

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (NASDAQ: AMCX) today reported financial results for the third quarter ended September 30, 2025. Chief Executive Officer Kristin Dolan said: “Our performance in the third quarter marks a key milestone in our transition from a cable networks business to a global streaming and technology focused content company. Streaming revenue growth accelerated and will represent our largest single source of domestic revenue this year. We again delivered healthy free cash flow and remain on track to achieve our increased outlook of $250 million in free cash for the full year. We have built the components of a modern media business that is nimble, independent and well suited to today’s environment and whatever comes next.” Operational...

HOBOKEN, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal first quarter ended September 30, 2025. “First quarter results met our expectations on the top- and bottom-line. During the quarter, organic net sales trends demonstrated sequential improvement in both our North America and International segments. Cost discipline and the decisive actions taken to streamline our cost structure drove a reduction in SG&A, and we are seeing early results from the execution against our ‘5 actions to win’, including benefits from pricing initiatives beginning to build,” said Alison Lewis, interim President and CEO.  Lewis continued,...

ROLLING MEADOWS, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”) (formerly known as Agrify Corporation), which delivers well-being to consumers through its portfolio of iconic licensed brands and hemp-derived THC products including Señorita THC Margaritas and RYTHM, today announced financial results for the quarter ended September 30, 2025.  Third Quarter 2025 Financial ResultsRevenue from continuing operations of $4.0 million, up 98% from $2.0 million in the prior quarter. $8.9 million operating loss from continuing operations. Cash balance of $35.6 million. Approximately 2.0 million shares, 7.6 million warrants outstanding and 6.2 million shares issuable upon conversion of outstanding convertible notes (excluding interest) as of September 30, 2025.Recent DevelopmentsThe Company’s...

All amounts in U.S. dollars unless otherwise stated TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the third quarter ended September 30, 2025. “Onex’ third quarter results reflect ongoing progress across the business,” said Bobby Le Blanc, CEO and President. “Our Private Equity teams continue to return meaningful capital to investors through strategic realizations, while planting the seeds for future growth through new investments. Our Credit team had another strong quarter bringing total capital raised or extended this year to more than $10 billion.”Financial Results (unaudited)($ millions except per share amounts) Three Months Ended Sept. 30 Nine Months Ended Sept. 30    2025 2024 2025 2024  Net earnings $ 39 $ 127 $ 436 $ 305  Net earnings per diluted...

Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce its financial and operational results for the third quarter ending September 30, 2025. The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% decrease in total liabilities, primarily due to the elimination of all liabilities associated with the previously issued convertible debentures, and an 8% reduction...

Financial Overview – Third QuarterRevenues of $165 Million, Down 41% From a Record a Year Ago Adjusted Pre-Tax Income of $20 Million, GAAP Pre-Tax Income of $12 Million Adjusted EPS of $0.13; GAAP Diluted EPS of $0.08Financial Overview – Nine MonthsRevenues of $532 Million, Down 18% From a Record a Year Ago Adjusted Pre-Tax Income of $53 Million, GAAP Pre-Tax Income of $30 Million Adjusted EPS of $0.51; GAAP Diluted EPS of $0.37Talent InvestmentYear-to-Date Added Twelve Partners and Nine Managing Directors Two Additional Partners and Two Additional Managing Directors to Join Firm in Coming Months Closed Acquisition of Devon Park AdvisorsCapital ManagementStrong Balance Sheet with $186 Million of Cash and No Debt Year-to-Date Retired More Than Six Million Shares and Share Equivalents through Purchase, Exchange...

Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjusted non-GAAP EBITDA of $59.6 million, an increase of 69.8% year-over-year Diluted GAAP income per share of $1.13 and record adjusted non-GAAP diluted earnings per share of $2.04 Raised 2025 total net revenue guidance to $854.0 million to $873.0 million, adjusted non-GAAP EBITDA to $221.0 million to $228.0 million, and adjusted non-GAAP diluted earnings per share of $7.37 to $7.64 Rare Disease net revenues expected to represent approximately 50% of total Company net revenues in 2025, including revised guidance for:Purified Cortrophin Gel net revenues of $347.0 million to $352.0 million, representing year-over-year growth of 75% to 78%, and ILUVIEN(1)...

VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three and nine months ended September 30, 2025. All dollar amounts are in US dollars ($). “Endeavour Silver delivered a strong third quarter, highlighted by a significant increase in production and robust revenue growth,” commented Dan Dickson, Chief Executive Officer. “With silver equivalent production up 88% year-over-year and operating cash flow more than doubling, we continue to demonstrate the strength of our mining operations and our team’s commitment to operational excellence. With the recent achievement of commercial production at Terronera in October, we are excited about the Company’s future growth and the combined performance of...